Highlights from the second quarter of 2020:
“The first signs of ad recovery became apparent in June in the Medicare Advantage sector of our DPNCheck business,” said Shai N. Gozani, MD, Ph.D., president and CEO of NeuroMetrix. “The timing and speed of recovery without equivalent remains uncertainty. We take this option to strengthen our balance sheet and expand our ad through newly informed collaborations with Biomedix and Yabao. Both have the possibility of having an imperative influence on the long-term of DPNCheck growing currencies. »
Finance:
The compabig apple w will organize a conference call and an Internet broadcast
NeuroMetrix will make a conference call at 8:00 a.m. EASTERN Time today, July 23, 2020. The call will be made in the United States at 844-787-0799, foreign to 661-378-9630, confirmation code 4284442 A replay can be obtained from two hours after the call to 855-859-2056 USA. And at foreign 404-537-3406, confirmation code 4284442. It will be available again for a week. The call can also be transmitted over the Internet and can be obtained at www.NeuroMetrix.com in Investor Relations.
About NeuroMetrix
NeuroMetrix, leading developers and brands of neurostimulation-based diagnostic and curative medical devices that are used worldwide. The combined apple has 3 FDA-approved advertising products. DPNCheck® is a point-of-service control used to evaluate peripheral neuropathy. ADVANCE ™ is a point-of-service device that provides nerve conduction studies to assist in the diagnosis and evaluation of patients suspected of having focal or systemic neuropathy. Quell® 2.0 is a portable neurostimulation device, compatible with a cellular application, indicated for symptom relief and persistent pain control and can be purchased without a prescription. Compabig Apple maintains an active and complex program of studies and progression. For more information, visit www.NeuroMetrix.com.
The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company’s or management’s expectations regarding the business, as well as events that could have a meaningful impact on the company’s revenues and cash resources. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on all aspects of the Company’s business, estimates of future performance, and the ability to successfully develop, receive regulatory clearance, commercialize and achieve market acceptance for any products. There can be no assurance that future developments will be those that the company has anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents that may be filed from time to time with the Securities and Exchange Commission or otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking statements.
Source: NeuroMetrix, Inc.
Thomas T.HigginsSVP and CFO [email protected]